SCYNEXIS, Inc. - Common Stock (SCYX)
Frequently Asked Questions About SCYNEXIS, Inc. - Common Stock (SCYX)
Are there any ongoing clinical trials conducted by SCYNEXIS?
Yes, SCYNEXIS is actively conducting clinical trials for its investigational products and therapies, focusing on evaluating their efficacy and safety in diverse patient populations.
Has SCYNEXIS received any FDA approvals?
Yes, SCYNEXIS received FDA approval for its lead product, BREXANOX, which represents a significant achievement in bringing a new treatment option to patients suffering from invasive fungal infections.
How does SCYNEXIS plan to grow in the future?
SCYNEXIS plans to grow by advancing its current product pipeline, exploring new therapeutic indications, and potentially acquiring or partnering with other companies to expand its portfolio of innovative treatments.
Is SCYNEXIS a publicly traded company?
Yes, SCYNEXIS, Inc. is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol SCYX, which allows investors to buy and sell shares of the company.
What challenges has SCYNEXIS faced?
Like many companies in the biotech industry, SCYNEXIS has faced challenges such as competition in the market, the need for substantial funding for ongoing research, and the complexities of gaining regulatory approval for new therapies.
What does SCYNEXIS, Inc. do?
SCYNEXIS, Inc. is a biotechnology company focused on the development of novel therapies for acute and chronic infections. The company specializes in the discovery, development, and commercialization of innovative drugs, particularly in the field of infectious diseases, including fungal infections.
What is SCYNEXIS's approach to clinical trials?
SCYNEXIS's approach to clinical trials involves rigorously testing its products through phased trials to ensure safety and efficacy, maintaining high standards of scientific integrity and regulatory compliance throughout the process.
What is the financial outlook for SCYNEXIS?
The financial outlook for SCYNEXIS depends on various factors, including the successful commercialization of its products, continued investment in research and development, and the ability to navigate industry dynamics and market demands.
What is the primary product of SCYNEXIS?
SCYNEXIS's primary product is BREXANOX, an innovative antifungal agent aimed at treating serious fungal infections, specifically designed to tackle challenging pathogens that are resistant to other medications.
What is the significance of SCYNEXIS's research and development?
SCYNEXIS's research and development efforts are significant because they focus on addressing unmet medical needs in the treatment of fungal infections, which are often overlooked and can result in severe patient outcomes.
What is the target market for SCYNEXIS's products?
The target market for SCYNEXIS's products includes healthcare providers and hospitals that treat patients with severe fungal infections, particularly those resistant to current therapies, as well as the broader pharmaceutical industry.
What partnerships does SCYNEXIS have?
SCYNEXIS has established various partnerships with academic institutions and pharmaceutical companies to facilitate research collaborations and accelerate the development of its therapeutic candidates.
What role does patient feedback play in SCYNEXIS's product development?
Patient feedback plays a critical role in SCYNEXIS's product development, as understanding the needs and experiences of patients helps the company tailor its drugs to better address the challenges faced by individuals with infections.
What types of infections does SCYNEXIS focus on treating?
SCYNEXIS primarily focuses on treating serious and life-threatening infections caused by resistant fungal pathogens, aiming to provide alternative treatment options for patients suffering from difficult-to-treat infections.
What was SCYNEXIS's initial public offering (IPO) date?
SCYNEXIS went public in 2013, marking a significant milestone for the company as it sought to raise capital for the ongoing development of its antifungal therapies.
When was SCYNEXIS, Inc. founded?
SCYNEXIS, Inc. was founded in 1996, and since then, it has continually focused on addressing significant medical needs in the field of infectious diseases through research and drug development.
Where can I find the latest news and updates about SCYNEXIS?
The latest news and updates about SCYNEXIS can be found on the company's official website, as well as through financial news outlets and regulatory filings available on the Nasdaq website.
Where is SCYNEXIS, Inc. headquartered?
SCYNEXIS, Inc. is headquartered in Durham, North Carolina, a hub for biotechnology and pharmaceutical companies, allowing for collaboration and innovation within the industry.
Who are the key executives at SCYNEXIS?
The key executives at SCYNEXIS include the CEO, Chief Medical Officer, and other senior leadership team members, each bringing extensive experience in the biopharmaceutical industry and a commitment to advancing the company's mission.
What is the current price of SCYNEXIS, Inc. - Common Stock?
The current price of SCYNEXIS, Inc. - Common Stock is 0.9500
When was SCYNEXIS, Inc. - Common Stock last traded?
The last trade of SCYNEXIS, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of SCYNEXIS, Inc. - Common Stock?
The market capitalization of SCYNEXIS, Inc. - Common Stock is 35.32M
How many shares of SCYNEXIS, Inc. - Common Stock are outstanding?
SCYNEXIS, Inc. - Common Stock has 37.18M shares outstanding.